Y. Ibrahim

发表

Stratification and therapeutic potential of PML in metastatic breast cancer

C. Caldas, O. Rueda, J. Baselga, 2016, Nature Communications.

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

Michael G. Kharas, A. Bergamaschi, S. Chandarlapaty, 2015, Science Translational Medicine.

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

P. Pandolfi, J. Baselga, L. Cantley, 2012, Cancer discovery.

Insulin-like growth factor-I and cancer risk.

D. Yee, Y. Ibrahim, 2004, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Progesterone Receptor-B Regulation of Insulin-Like Growth Factor–Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2

Adrian V. Lee, S. Byron, D. Yee, 2008, Molecular Cancer Research.

The IGF Pathway Regulates ER (cid:1) through a S6K1-Dependent Mechanism in Breast Cancer Cells

D. Yee, X. Cui, Y. Ibrahim, 2011 .

Targeting a cell state common to triple-negative breast cancers

Markus K. Muellner, G. Superti-Furga, K. Bennett, 2015, Molecular systems biology.

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

W. Hahn, J. Baselga, S. Kim, 2013, The Journal of clinical investigation.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

C. Caldas, J. Baselga, S. Cairo, 2018, EMBO molecular medicine.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

P. Kristel, C. Caldas, O. Rueda, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Lei He, Violeta Serra, Maurizio Scaltriti, 2012, Cancer discovery.

Dual Mtorc1/2 and Her2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-her2 Therapy Statement of Translational Relevance

J. Baselga, J. Tabernero, C. Rommel, 2022 .

Cancer Therapy : Preclinical Dual mTORC 1 / 2 and HER 2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER 2 Therapy

J. Baselga, J. Tabernero, C. Rommel, 2012 .

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

Sarat Chandarlapaty, Violeta Serra, Maurizio Scaltriti, 2011, Proceedings of the National Academy of Sciences.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

S. Chandarlapaty, J. Baselga, N. Rosen, 2011, Oncogene.

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers

J. Baselga, A. Pandiella, J. Arribas, 2013, Oncogene.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

J. Baselga, J. Tabernero, P. Nuciforo, 2015, Clinical Cancer Research.

BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition PI 3 K Inhibition Impairs BRCA 1 / 2 Expression and Sensitizes

J. Baselga, L. Ellisen, O. Díez, 2012 .

PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

C. Caldas, P. Nuciforo, R. Dienstmann, 2021, British Journal of Cancer.

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

G. Mills, C. Caldas, P. Nuciforo, 2020, Clinical Cancer Research.

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer

N. Rosen, Manway Liu, J. Baselga, 2013, Science Translational Medicine.

Elkabets-Mutant Breast Cancer PIK 3 CA Inhibitors in α mTORC 1 Inhibition Is Required for Sensitivity to PI 3 K p 110

Manway Liu, J. Baselga, M. Mino‐Kenudson, 2013 .

Insulin-like growth factor-I and breast cancer therapy.

D. Yee, Y. Ibrahim, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue

J. Blenis, P. Seale, J. Baur, 2016, Genes & development.

The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.

Adrian V. Lee, D. Yee, X. Cui, 2011, Molecular endocrinology.

In Vitro Pharmacodynamic Analysis of Single Daily Dosing versus Conventional Dosing of Gentamicin Administered with Penicillin Against Enterococcus faecalis

L. B. Hovde, J. Rotschafer, Y. Ibrahim, 2001, Pharmacotherapy.

Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer

Adrian V. Lee, C. Fan, C. Perou, 2016, PloS one.

Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747)

Manway Liu, J. Baselga, M. Mino‐Kenudson, 2018 .

An affinity tool for the isolation of endogenous active mTORC1 from various cellular sources

Y. Ibrahim, A. Mutvei, Spyridon Pantelios, 2023, The Journal of biological chemistry.

Abstract 653: Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models

J. Baselga, J. Tabernero, C. Rommel, 2011 .

Abstract 648: Combined PI3K and MEK inhibition in patient-derived xenografts generated from recurrent triple negative breast cancer

J. Baselga, M. Scaltriti, V. Serra, 2011 .

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

J. Baselga, J. Tabernero, C. Rommel, 2012, Clinical Cancer Research.

Stratification and therapeutic potential of PML in metastatic breast cancer

O. Rueda, J. Baselga, R. Gomis, 2016, Nature Communications.

The IGF Pathway Regulates ER-α through A S6K1-Dependent Mechanism in Breast Cancer Cells

Adrian V. Lee, D. Yee, X. Cui, 2011 .